F.D.A. Advisers Set to Discuss Merck’s Covid Pill

If an expert committee votes to recommend it, the drug, molnupiravir, could be authorized within days for patients at high risk of severe illness.

View original article
Contributor: Rebecca Robbins and Carl Zimmer